MindRank Advances to Phase 3 Trial with China's First AI-Driven Drug, Cutting R&D Costs by 60%
The firm targeted authorization during the latter part of 2028, setting the stage for an introducti…
The firm targeted authorization during the latter part of 2028, setting the stage for an introducti…